Presentation by Joe Rininger
LBG’s Joe Rininger, Ph.D. will join “the brightest minds in bioprocessing” at BPI West on February 27 – March 2 in San Diego.
Dr. Rininger, who is speaking and participating in a panel discussion, will share his expertise on cell and gene therapy CDMO selection as well as manufacturing best practices.
His presentation, titled “Key Attributes and Intangible Considerations of Cell and Gene Therapy CDMO Selection by Innovator Companies,” will take place on March 1 at 4 p.m.
“The selection of a CDMO is one of the most important decisions and relationships to make and foster as part of advanced therapy product development and advancement,” says Dr. Rininger. “My presentation will provide the weighing of key attributes and cultural fit aspects surrounding the CDMO selection process undertaken by product developers and some potential impacts from the SARS-CoV-2 pandemic.”
The panel discussion, which is titled “CGT CDMO Selection and Manufacturing Best Practices,” will explore vetting a CDMO, selection criteria, quality control, quality assurance, life cycle management, and much more. The discussion takes place March 1 at 4:30 p.m.
Dr. Rininger has more than 20 years of experience in basic biomedical research and biopharmaceutical product development, manufacturing, and program management with an emphasis on vaccines and gene therapy. At LBG, he leads product development engagements with cell and gene therapy companies and strategic market research with service providers to model the cell and gene therapy/viral vector space.
